PFE

Pfizer Inc. (PFE) | Rumor.io

Pfizer

PFE

Attention (50-day avg)0.05%

Attention rank (50-day avg)#173

Bullish sentiment (50-day avg)92%

Price to earnings ratio37.8

Market capitalization163.7B

Earnings per share0.76

Dividend yield (TTM)5.99%

Revenue (annual)62.6B

Net income (annual)7.8B

Social

What share of all stock conversation is about PFE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.04% -0.01	0.05% -0.08	0.06% +0.01	0.06% -0.04

Sep 29

Pfizer announced they will present P3 Breast Cancer results on 2026-10-24 for Tucatinib, and also present P3 Bladder Cancer results on 2026-10-24 for Enfortumab vedotin, P3 Non-Small-Cell Lung Cancer results on 2026-10-25 for Sigvotatug Vedotin, P3 Prostate Cancer results on 2026-10-23 for Mevrometostat, and P3 Transitional Cell Carcinoma|Bladder Cancer results on 2026-10-23 for Enfortumab vedotin.
The company's new and acquired portfolio continues to grow at a solid rate, and Pfizer has extended commercial runway for the Vyndaqel family, which should offset some of the headwinds in the LOE phase.
The pharmaceutical giant is working to rebuild growth through oncology, obesity treatments, strategic acquisitions, cost reductions, and a new wave of pipeline products, with the company's current investment story to be understood through a detailed framework.

Generated by AI

Sentiment

Of the messages about PFE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	93.22% -6.57	96.84% +16.66	79.27% +4.78
Bearish	0% 0	6.78% +6.57	3.16% -16.66	20.73% -4.78

Bullish· Sep 3

Pfizer's $1 billion deal with Medicus for an antibody drug conjugate is a massive and significant development, highlighting the company's commitment to innovation and growth.
The deal's worth is estimated at $1 billion, indicating a substantial investment in Medicus's technology, which could lead to breakthroughs in cancer treatment and further establish Pfizer as a leader in the pharmaceutical industry.
Pfizer's stock price has been performing well, printing a new 52-week high and with analysts predicting further growth, with some even believing the stock could reach $35 in the near future.

Bearish· Aug 19

Pfizer's stock price has been declining, with one user selling out at $28.20 and another expressing fear about their investment.
The company's reputation has been damaged, with one user stating that Pfizer's vaccine was a "scam" and another expressing concerns about the company's ability to recover from past controversies.
The company's financial prospects are uncertain, with one user predicting a potential bankruptcy and another stating that Pfizer will likely give back all its gains in the coming days.

Generated by AI

Topics

Of the messages about PFE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Controversies	0%	2.05%	0.21%	0.95%
Macro	18.18%	86.36%	50.38%	54.74%
Announcements	63.64%	8.23%	4.69%	13.92%
Technical Analysis	0%	1.82%	2.28%	2.39%
Analysts	18.18%	1.36%	41.74%	24.2%
Earnings	0%	0.18%	0.7%	3.79%

Earnings· Aug 5

Pfizer reports Q2 earnings, beating expectations with $15.03B in revenue and $0.77 in adj. EPS, outperforming the street's forecast of $14.4B in revenue and $0.68 in adj. EPS.
The company raises the midpoint of its 2026 revenue guidance to $60.5B-$62.5B, and expands its restructuring plan to include an additional $2.5B in cost-cutting measures through 2029.
Despite the improved outlook, Pfizer faces an estimated $35B patent cliff by the end of the decade, which could impact its long-term growth prospects and investor confidence.

Analysts· Oct 16

Pfizer's stock price was upgraded to Buy from Hold at Jefferies with a new price target of $39.
Several analysts have cut their price targets for Pfizer, including Citigroup to $35 and BMO to $33, but Jefferies remains bullish on the stock.
Analysts are expecting Pfizer's vaccine Comirnaty and Paxlovid to remain among the company's largest products over the next several years, despite lowered COVID-19 product sales guidance.

Announcements· Aug 5

Pfizer reports Q2 results, exceeding expectations with $15.03B in sales and a 18% growth in non-COVID business, prompting an increase in 2026 guidance.
The company's strong performance is attributed to its solid and operational transition, with its BPA and sales figures surpassing expectations.
Pfizer's acquisition of Seagen is yielding real value, with the Seagen-related product portfolio growing by 21%, and the company also reporting strong clinical data for its Padcev and Keytruda combination in bladder cancer treatment.

Controversies· Nov 5

A Delaware judge has denied Pfizer's request to temporarily block Novo Nordisk's $10 billion acquisition of Metsera, supporting Novo's takeover strategy.
The US Federal Trade Commission has raised concerns that Novo Nordisk's proposed acquisition of Metsera could breach procedural requirements under federal premerger review laws.
Pfizer has responded to the Delaware Chancery Court ruling, stating it remains confident in the merits of its claims and believes Metsera has acted in breach of its contractual obligations.

Macro· May 6

The US stock market, led by the Nasdaq, reached record highs, with the S&P 500 and Dow Jones also gaining.
Materials and technology shares drove the gains, with Intel surging 12.9% on reports of potential chip foundry partnerships.
Pfizer delivered results above expectations, along with AMD and Pinterest, in a strong showing for the US stock market.

Technical Analysis· Jul 1

Pfizer $PFE has formed a Death Cross, a bearish signal that occurred last in November 2024, which led to a bear market within 5 months.
The stock has broken its year-to-date low, aiming for the 52-week low, indicating a potential further decline.
The Death Cross has triggered a bearish signal for Pfizer $PFE, similar to the one in November 2024, which resulted in a bear market within 5 months.

Generated by AI

Community

Of the messages about PFE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.66%	29.06%	66.32%	39.68%
Newcomers	5.34%	70.94%	33.68%	60.32%

Regulars· Sep 29

Pfizer is presenting P3 Breast Cancer results on 2026-10-24 for Tucatinib.
Pfizer is co-developing an ADC against CD228 with Medicus Pharma, with Medicus retaining the worldwide license and Pfizer funding the development.
Pfizer is presenting P2 Non-Small-Cell Lung Cancer results on 2026-10-26 for PF-08634404.

Newcomers· Sep 25

Newcomers are focusing on the comparison between Pfizer's COVID-19 vaccine development and BioNTech, with some acknowledging Pfizer's role in mass-producing the vaccine despite not developing it.
Many newcomers are discussing the cost of developing and distributing the vaccine, with some pointing out that Pfizer spent $2 billion to bring it to market.
Some newcomers are using technical analysis to predict future price movements for Pfizer stock, with one user identifying a potential Gartley/Bat pattern and another observing a bullish flag.

Generated by AI

News

With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap? | The Motley Fool

While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.

16h agoThe Motley Fool

Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?

23h agoYahoo Finance

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACsBRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and devel

1d agoYahoo Finance

From Pfizer to UPS, the newest members of the AIQ 75 share the secrets to upping their AI game | Fortune

How Pfizer, Lumen, Cisco, UPS, Palo Alto Networks, and Thermo Fisher are moving AI beyond pilots—using it to reshape drug discovery, networks, logistics, cybersecurity, and daily work.

1d agoFortune

Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE)

Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.

1d agoSeeking Alpha

Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE)

Delaware judge lets Monsanto’s mRNA patent lawsuits vs Pfizer, BioNTech, and Moderna proceed. Read more here.

1d agoSeeking Alpha

Also Discussed

Investors talking about PFE also mention

#	Name	Attention
1	BioNTech SEBNTX	0%+0
2	Moderna Inc.MRNA	0.1%+0.03
3	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
4	Merck & Co., Inc.MRK	0.01%-0.06
5	Johnson & JohnsonJNJ	0%-0.06
6	Novartis AG Sponsored ADRNVS	0%-0.01
7	Bristol-Myers Squibb CompanyBMY	0.01%0
8	MTSR - Metsera, Inc.	——
9	Novavax Inc.NVAX	0.03%-0.01
10	Sanofi ADRSNY	0%-0.01

Pfizer Inc.

Healthcare
Drug Manufacturers - General

Pfizer Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes medicines and vaccines for patients worldwide. Its current portfolio spans oncology, internal medicine, vaccines, inflammation and immunology, rare diseases, and hospital-based therapies, supported by a broad commercial presence across major healthcare markets. Pfizer also offers consumer health products and continues to operate across both prescription and non-prescription categories through its diversified healthcare platform. The company works with research, regulatory, and healthcare partners to deliver treatments used in primary care, specialty care, and hospital settings. Founded in 1849 and headquartered in New York, Pfizer remains a major name in the pharmaceutical industry, with a role centered on advancing access to established therapies and newly approved medicines across global markets.

Website

Location

66 Hudson Boulevard East

New York, NY, 10001-2192

United States

Social

What share of all stock conversation is about PFE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.04% -0.01	0.05% -0.08	0.06% +0.01	0.06% -0.04

Sep 29

Pfizer announced they will present P3 Breast Cancer results on 2026-10-24 for Tucatinib, and also present P3 Bladder Cancer results on 2026-10-24 for Enfortumab vedotin, P3 Non-Small-Cell Lung Cancer results on 2026-10-25 for Sigvotatug Vedotin, P3 Prostate Cancer results on 2026-10-23 for Mevrometostat, and P3 Transitional Cell Carcinoma|Bladder Cancer results on 2026-10-23 for Enfortumab vedotin.
The company's new and acquired portfolio continues to grow at a solid rate, and Pfizer has extended commercial runway for the Vyndaqel family, which should offset some of the headwinds in the LOE phase.
The pharmaceutical giant is working to rebuild growth through oncology, obesity treatments, strategic acquisitions, cost reductions, and a new wave of pipeline products, with the company's current investment story to be understood through a detailed framework.

Generated by AI

Sentiment

Of the messages about PFE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	93.22% -6.57	96.84% +16.66	79.27% +4.78
Bearish	0% 0	6.78% +6.57	3.16% -16.66	20.73% -4.78

Bullish· Sep 3

Pfizer's $1 billion deal with Medicus for an antibody drug conjugate is a massive and significant development, highlighting the company's commitment to innovation and growth.
The deal's worth is estimated at $1 billion, indicating a substantial investment in Medicus's technology, which could lead to breakthroughs in cancer treatment and further establish Pfizer as a leader in the pharmaceutical industry.
Pfizer's stock price has been performing well, printing a new 52-week high and with analysts predicting further growth, with some even believing the stock could reach $35 in the near future.

Bearish· Aug 19

Pfizer's stock price has been declining, with one user selling out at $28.20 and another expressing fear about their investment.
The company's reputation has been damaged, with one user stating that Pfizer's vaccine was a "scam" and another expressing concerns about the company's ability to recover from past controversies.
The company's financial prospects are uncertain, with one user predicting a potential bankruptcy and another stating that Pfizer will likely give back all its gains in the coming days.

Generated by AI

Topics

Of the messages about PFE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Controversies	0%	2.05%	0.21%	0.95%
Macro	18.18%	86.36%	50.38%	54.74%
Announcements	63.64%	8.23%	4.69%	13.92%
Technical Analysis	0%	1.82%	2.28%	2.39%
Analysts	18.18%	1.36%	41.74%	24.2%
Earnings	0%	0.18%	0.7%	3.79%

Earnings· Aug 5

Pfizer reports Q2 earnings, beating expectations with $15.03B in revenue and $0.77 in adj. EPS, outperforming the street's forecast of $14.4B in revenue and $0.68 in adj. EPS.
The company raises the midpoint of its 2026 revenue guidance to $60.5B-$62.5B, and expands its restructuring plan to include an additional $2.5B in cost-cutting measures through 2029.
Despite the improved outlook, Pfizer faces an estimated $35B patent cliff by the end of the decade, which could impact its long-term growth prospects and investor confidence.

Analysts· Oct 16

Pfizer's stock price was upgraded to Buy from Hold at Jefferies with a new price target of $39.
Several analysts have cut their price targets for Pfizer, including Citigroup to $35 and BMO to $33, but Jefferies remains bullish on the stock.
Analysts are expecting Pfizer's vaccine Comirnaty and Paxlovid to remain among the company's largest products over the next several years, despite lowered COVID-19 product sales guidance.

Announcements· Aug 5

Pfizer reports Q2 results, exceeding expectations with $15.03B in sales and a 18% growth in non-COVID business, prompting an increase in 2026 guidance.
The company's strong performance is attributed to its solid and operational transition, with its BPA and sales figures surpassing expectations.
Pfizer's acquisition of Seagen is yielding real value, with the Seagen-related product portfolio growing by 21%, and the company also reporting strong clinical data for its Padcev and Keytruda combination in bladder cancer treatment.

Controversies· Nov 5

A Delaware judge has denied Pfizer's request to temporarily block Novo Nordisk's $10 billion acquisition of Metsera, supporting Novo's takeover strategy.
The US Federal Trade Commission has raised concerns that Novo Nordisk's proposed acquisition of Metsera could breach procedural requirements under federal premerger review laws.
Pfizer has responded to the Delaware Chancery Court ruling, stating it remains confident in the merits of its claims and believes Metsera has acted in breach of its contractual obligations.

Macro· May 6

The US stock market, led by the Nasdaq, reached record highs, with the S&P 500 and Dow Jones also gaining.
Materials and technology shares drove the gains, with Intel surging 12.9% on reports of potential chip foundry partnerships.
Pfizer delivered results above expectations, along with AMD and Pinterest, in a strong showing for the US stock market.

Technical Analysis· Jul 1

Pfizer $PFE has formed a Death Cross, a bearish signal that occurred last in November 2024, which led to a bear market within 5 months.
The stock has broken its year-to-date low, aiming for the 52-week low, indicating a potential further decline.
The Death Cross has triggered a bearish signal for Pfizer $PFE, similar to the one in November 2024, which resulted in a bear market within 5 months.

Generated by AI

Community

Of the messages about PFE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.66%	29.06%	66.32%	39.68%
Newcomers	5.34%	70.94%	33.68%	60.32%

Regulars· Sep 29

Pfizer is presenting P3 Breast Cancer results on 2026-10-24 for Tucatinib.
Pfizer is co-developing an ADC against CD228 with Medicus Pharma, with Medicus retaining the worldwide license and Pfizer funding the development.
Pfizer is presenting P2 Non-Small-Cell Lung Cancer results on 2026-10-26 for PF-08634404.

Newcomers· Sep 25

Newcomers are focusing on the comparison between Pfizer's COVID-19 vaccine development and BioNTech, with some acknowledging Pfizer's role in mass-producing the vaccine despite not developing it.
Many newcomers are discussing the cost of developing and distributing the vaccine, with some pointing out that Pfizer spent $2 billion to bring it to market.
Some newcomers are using technical analysis to predict future price movements for Pfizer stock, with one user identifying a potential Gartley/Bat pattern and another observing a bullish flag.

Generated by AI

Pfizer

Social

Sep 29

Bullish· Sep 3

Bearish· Aug 19

Earnings· Aug 5

Analysts· Oct 16

Announcements· Aug 5

Controversies· Nov 5

Macro· May 6

Technical Analysis· Jul 1

Regulars· Sep 29

Newcomers· Sep 25

With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap? | The Motley Fool

Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

From Pfizer to UPS, the newest members of the AIQ 75 share the secrets to upping their AI game | Fortune

Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE)

Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE)

Also Discussed

Pfizer Inc.

Company Information

Location

With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap? | The Motley Fool

Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

From Pfizer to UPS, the newest members of the AIQ 75 share the secrets to upping their AI game | Fortune

Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE)

Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE)

Also Discussed

Social

Sep 29

Bullish· Sep 3

Bearish· Aug 19

Earnings· Aug 5

Analysts· Oct 16

Announcements· Aug 5

Controversies· Nov 5

Macro· May 6

Technical Analysis· Jul 1

Regulars· Sep 29

Newcomers· Sep 25